Today: 9 April 2026
Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE
12 January 2026
1 min read

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

New York, Jan 12, 2026, 15:40 ET — Regular session

Shares of Dave Inc (DAVE.O) dropped 8.8% to $218.29 in late-afternoon trading Monday, after earlier fluctuating between $212.10 and $247.74. The fintech’s stock had closed Friday at $239.35, with roughly 1.1 million shares changing hands by mid-afternoon, according to market data.

The drop came as investors backed away from credit-sensitive stocks following U.S. President Donald Trump’s call for a one-year cap on credit card interest rates at 10%, starting Jan. 20. On the docket for Tuesday is the U.S. consumer price index (CPI), a crucial inflation measure that could shift expectations around Federal Reserve rate cuts. “We need to see some type of action before the market will actually react to it in a meaningful way,” said Jordan Rizzuto, chief investment officer at GammaRoad Capital Partners.

U.S. stocks were creeping up, the Nasdaq gaining roughly 0.5% and the S&P 500 reaching an intraday record, despite weakness in the financial sector. Peter Cardillo, chief market economist at Spartan Capital Securities in New York, noted the investigation headline involving Fed Chair Jerome Powell had been “telegraphed,” so the market shrugged it off.

Dave’s slump mirrored a wider slide in consumer-finance and fintech stocks. Upstart fell roughly 7.0%, Affirm dropped 6.7%, and SoFi declined 2.8%. LendingClub, however, saw minimal movement.

Dave positions itself as a neobank and fintech platform, offering products like ExtraCash — a 0% interest overdraft through a banking partner — and Dave Checking, a digital deposit account. In 2024, it reported roughly $347 million in revenue and net income near $58 million, according to LSEG data on the Reuters company page.

Monday’s moves can hit smaller consumer fintechs hard, as changes in rate expectations swiftly affect perceptions of funding costs and borrower strain. When sentiment turns sour on lenders, selling often goes too far.

Legal and regulatory clouds loom as well. In late 2024, the U.S. Justice Department lodged a complaint and launched a civil enforcement action against Dave and its CEO, Jason Wilk. They allege the company deceived users over cash advances and imposed hidden fees. Dave pushed back, calling many of the claims inaccurate and pledging a defense. Reuters

Another risk is that policy chatter hardens into actual rules. A rate cap designed for credit cards won’t necessarily apply to every consumer-finance product. Yet investors often sell off the entire sector upfront, then figure out the specifics afterward.

Investors now turn to Tuesday’s CPI data and the start of major U.S. bank earnings, with JPMorgan Chase leading off on Jan. 13. These updates could shift views on interest rates and consumer credit trends in the coming weeks. Reuters

Stock Market Today

  • 3 Reasons to Sell Deere & Co (DE) and 1 Stock to Buy Instead
    April 9, 2026, 3:49 PM EDT. Deere & Co (DE) has outperformed the S&P 500 with a 33.6% gain since October 2025, yet experts advise caution. Sales growth has been modest at 4.8% compounded annually over five years, below industrial sector standards. Return on Invested Capital (ROIC), a key profitability measure, has declined significantly. Deere's high debt load stands at $62.48 billion, over seven times its EBITDA, raising financial risk. The stock trades at 30.5 times forward earnings, reflecting high market optimism. Analysts suggest waiting for improved profitability or debt reduction. Instead, they recommend considering a leading digital advertising platform positioned in the growing creator economy as a better buy opportunity.

Latest article

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

9 April 2026
The average 30-year fixed mortgage rate fell to 6.37% from 6.46%, Freddie Mac said Thursday. Purchase mortgage applications rose 1% last week but remained 7% lower than a year ago, according to the Mortgage Bankers Association. Refinance activity dropped 3%. Mortgage News Daily’s index showed the 30-year fixed at 6.38%, with the 10-year Treasury near 4.27%.
Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

9 April 2026
Bitcoin traded near $72,000 Thursday, up 0.3%, after earlier slipping on renewed Middle East tensions. U.S. spot bitcoin ETFs saw $471.4 million in inflows April 6 but $93.9 million in outflows April 8, as Morgan Stanley’s new MSBT fund debuted with $30.6 million. Ether fell 0.9% to $2,210.56. Bitcoin remains 43% below its October 2025 record high.
Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

9 April 2026
Spot silver jumped 2.9% to $76.24 an ounce Thursday, extending gains after a U.S.-Iran ceasefire and a weaker dollar. Gold rose 1.63% to $4,793.07. Analysts warned the truce remains fragile, with markets watching for March U.S. inflation data due Friday. Oil fell below $100 but tensions persisted in the Middle East.
Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

9 April 2026
Spot gold rose 1.6% to $4,789.67 an ounce by 1:30 p.m. ET Thursday as the U.S. dollar weakened and Treasury yields slipped. U.S. gold futures settled 0.9% higher at $4,818.00. Traders watched a fragile ceasefire between Washington and Tehran and awaited Friday’s U.S. inflation data. March saw gold’s steepest monthly drop since 2008, according to China’s central bank.
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus
Previous Story

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface
Next Story

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

Go toTop